未登录

J

Jonathan Kish

Boehringer Ingelheim

H指数:22

被引数:2,014

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Real-world outcomes of pomalidomide therapy after lenalidomide induction in relapsed/refractory multiple myeloma

来那度胺诱导复发/难治性多发性骨髓瘤后波马利多胺治疗的真实世界结果

FUTURE ONCOLOGY

IF2.6

2021-11-176

OA

Real-world utilization and outcomes of immune-based combination therapies or tyrosine kinase inhibitors (TKIs) for advanced renal cell carcinoma (aRCC)

ANNALS OF ONCOLOGY

IF65.4

2021-09-010

OAAI

Second-line Afatinib or Chemotherapy Following Immunochemotherapy for the Treatment of Metastatic, Squamous Cell Carcinoma of the Lung: Real-world Effectiveness and Safety From a Multisite Retrospective Chart Review in the USA

CLINICAL LUNG CANCER

IF3.3

2021-07-013

OAAI

Effectiveness of Eribulin in Metastatic Breast Cancer: 10 Years of Real-World Clinical Experience in the United States (vol 38, pg 2213, 2021)

ADVANCES IN THERAPY

IF4

2021-05-161

OAAI

Real-world treatment patterns and clinical effectiveness of eribulin in HR+/HER2-metastatic breast cancer patients in the United States

ANNALS OF ONCOLOGY

IF65.4

2021-05-010

OAAI

Effectiveness of Eribulin in Metastatic Breast Cancer: 10 Years of Real-World Clinical Experience in the United States (Jan, 10.1007/s12325-020-01613-6, 2021)

ADVANCES IN THERAPY

IF4

2021-04-070

OAAI

Effectiveness of Eribulin in Metastatic Breast Cancer: 10 Years of Real-World Clinical Experience in the United States

ADVANCES IN THERAPY

IF4

2021-01-2419

OAAI

Use of Real-World Evidence to Support FDA Approval of Oncology Drugs

使用真实世界的证据来支持FDA批准肿瘤药物

VALUE IN HEALTH

IF6

2020-10-0171

OAAI

Physician treatment of metastatic triple-negative breast cancer in the immuno-oncology era: a discrete choice experiment

在免疫肿瘤学时代，医生对转移性三阴性乳腺癌的治疗: 一项离散选择实验

FUTURE ONCOLOGY

IF2.6

2020-09-211

OAAI

Real-world treatment patterns and clinical effectiveness outcomes of eribulin in metastatic breast cancer patients in community oncology centers in the United States

ANNALS OF ONCOLOGY

IF65.4

2020-09-010

OAAI

Lenvatinib and Subsequent Therapy for Radioactive Iodine-Refractory Differentiated Thyroid Cancer: A Real-World Study of Clinical Effectiveness in the United States

ADVANCES IN THERAPY

IF4

2020-05-0727

OAAI

Real-world risk assessment and treatment initiation among patients with myelofibrosis at community oncology practices in the United States

ANNALS OF HEMATOLOGY

IF2.4

2020-05-0711

OAAI

Real-world dosing and CBC monitoring in patients with metastatic breast cancer during palbociclib plus letrozole therapy

CANCER RESEARCH

IF16.6

2020-02-150

PRE

Real-world incidence and cost of pneumonitis post-chemoradiotherapy for Stage III non-small-cell lung cancer

III期非小细胞肺癌放化疗后肺炎的真实世界发病率和费用

FUTURE ONCOLOGY

IF2.6

2019-12-058

OAAI

Observational study of clinical outcomes of eribulin mesylate in metastatic breast cancer after cyclin-dependent kinase 4/6 inhibitor therapy

FUTURE ONCOLOGY

IF2.6

2019-10-2911

OAAI

TREATMENT PATTERNS AND COST ANALYSIS AMONG PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA

VALUE IN HEALTH

IF6

2019-05-010

OAAI

PERCEPTIONS AMONG COMMUNITY ONCOLOGISTS AND RHEUMATOLOGISTS ON DIRECT TO CONSUMER ADVERTISING (DTCA) IN HEALTHCARE

VALUE IN HEALTH

IF6

2019-05-010

OAAI

CANCER PATIENT ENGAGEMENT IN 2018-COMMUNITY PROVIDERS PERSPECTIVES ON DIGITAL DATA AND COMMUNICATION AT THE BEDSIDE

VALUE IN HEALTH

IF6

2019-05-010

OAAI

Targeted agents or immuno-oncology therapies as first-line therapy for BRAF-mutated metastatic melanoma: a real-world study

靶向药物或免疫肿瘤疗法作为BRAF突变转移性黑色素瘤的一线治疗: 一项真实世界研究

FUTURE ONCOLOGY

IF2.6

2019-02-2535

OAAI

Outcomes of real-world use of eribulin plus trastuzumab for HER2-positive metastatic breast cancer

CANCER RESEARCH

IF16.6

2019-02-150

PRE